{
  "timeline": [
    {
      "date": "2005/2",
      "category": "組織再編",
      "region": "",
      "importance": 2,
      "event": "第一製薬と三共が経営統合基本合意",
      "detail": "株式移転による共同持株会社設立に両社が合意",
      "significance": "国内製薬業界再編の一角を成す統合の起点",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/5",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "経営統合契約を締結",
      "detail": "両社取締役会で当社設立を決議",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/6",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "両社株主総会で当社設立を承認",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/9",
      "category": "会社設立",
      "region": "",
      "importance": 3,
      "event": "第一三共株式会社設立・東証一部上場",
      "detail": "株式移転により三共・第一製薬の完全親会社として発足",
      "significance": "国内大手製薬の統合により新たな事業体が誕生",
      "source": "有価証券報告書"
    },
    {
      "date": "2005/12",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "第一三共ヘルスケア株式会社を設立",
      "detail": "OTC事業の受け皿となる子会社",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2006/3",
      "category": "組織再編",
      "region": "米州",
      "importance": 1,
      "event": "米国拠点を第一三共Inc.に商号変更",
      "detail": "三共ファルマInc.を存続会社に第一ファーマ系3社を合併",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2006/4",
      "category": "企業買収",
      "region": "",
      "importance": 2,
      "event": "ゼファーマ株式会社を取得",
      "detail": "アステラス製薬よりOTC事業子会社の全株式を取得",
      "significance": "OTC事業強化に向けた統合直後の国内買収",
      "source": "有価証券報告書"
    },
    {
      "date": "2006/7",
      "category": "組織再編",
      "region": "欧州",
      "importance": 1,
      "event": "欧州拠点を第一三共ヨーロッパGmbHに商号変更",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2007/4",
      "category": "組織再編",
      "region": "",
      "importance": 3,
      "event": "三共・第一製薬を吸収合併",
      "detail": "当社が旧2社を吸収合併し事業会社化",
      "significance": "持株会社方式から一体運営への移行完了",
      "source": "有価証券報告書"
    },
    {
      "date": "2007/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "第一三共ヘルスケアがゼファーマを吸収合併",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2008/11",
      "category": "企業買収",
      "region": "その他",
      "importance": 4,
      "event": "ランバクシー・ラボラトリーズを子会社化",
      "detail": "インド大手ジェネリックメーカーの株式取得により子会社化",
      "significance": "新興国ジェネリック市場への大型参入だったがのれん減損を招いた",
      "source": "有価証券報告書"
    },
    {
      "date": "2009/3",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "初の純損失計上",
      "detail": "ランバクシー関連ののれん・無形資産減損等を主因とする特別損失計上",
      "significance": "統合後初の巨額赤字でM&A戦略の難しさが表面化",
      "source": "有価証券報告書",
      "amount": "純損失▲2155億円"
    },
    {
      "date": "2009/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "庄田隆から中山讓治へ社長交代",
      "detail": "統合後初の社長交代",
      "significance": "統合初代社長から世代交代",
      "source": "有価証券報告書"
    },
    {
      "date": "2010/4",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "第一三共エスファ株式会社を設立",
      "detail": "国内ジェネリック事業の受け皿",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/4",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "北里第一三共ワクチン株式会社を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/4",
      "category": "企業買収",
      "region": "米州",
      "importance": 2,
      "event": "プレキシコンInc.を子会社化",
      "detail": "米国創薬ベンチャー",
      "significance": "低分子標的薬パイプライン強化の一手",
      "source": "有価証券報告書"
    },
    {
      "date": "2011/11",
      "category": "",
      "region": "中国",
      "importance": 1,
      "event": "第一三共（中国）投資有限公司を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2012/4",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "ジャパンワクチン株式会社を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2014/11",
      "category": "企業買収",
      "region": "米州",
      "importance": 2,
      "event": "アンビット・バイオサイエンシズCorp.を子会社化",
      "detail": "米国バイオ企業",
      "significance": "FLT3阻害剤キザルチニブ等のパイプライン獲得",
      "source": "有価証券報告書"
    },
    {
      "date": "2015/3",
      "category": "組織再編",
      "region": "",
      "importance": 3,
      "event": "ランバクシー子会社化を解消",
      "detail": "サン・ファーマシューティカルによる吸収合併に伴い連結除外",
      "significance": "2008年買収から約6年で新興国ジェネリック戦略を実質撤退",
      "source": "有価証券報告書"
    },
    {
      "date": "2016/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "中山讓治から眞鍋淳へ社長交代",
      "detail": "",
      "significance": "次期中計を担う経営体制への移行",
      "source": "有価証券報告書"
    },
    {
      "date": "2017/11",
      "category": "企業買収",
      "region": "",
      "importance": 1,
      "event": "北里第一三共ワクチンを完全子会社化",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2018/8",
      "category": "",
      "region": "",
      "importance": 1,
      "event": "第一三共バイオテック株式会社を設立",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/1",
      "category": "組織再編",
      "region": "米州",
      "importance": 1,
      "event": "ルイトポルド社をアメリカン・リージェントInc.に改称",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2019/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "ジャパンワクチン株式会社を解散",
      "detail": "",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/4",
      "category": "株式上場",
      "region": "",
      "importance": 1,
      "event": "東証プライム市場へ移行",
      "detail": "市場区分見直しに伴い第一部からプライムへ",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2022/6",
      "category": "社長交代",
      "region": "",
      "importance": 2,
      "event": "眞鍋淳から奥澤宏幸へ社長交代",
      "detail": "眞鍋は会長兼CEOに",
      "significance": "エンハーツ成長加速期の実行責任者交代",
      "source": "有価証券報告書"
    },
    {
      "date": "2023/10",
      "category": "企業買収",
      "region": "",
      "importance": 4,
      "event": "Merck（Merck & Co., Inc.）と戦略的提携",
      "detail": "HER3-DXd・I-DXd・DS-6000の共同開発・共同販促契約締結",
      "significance": "5DXd ADCs戦略を米メルクとの資本関係なしで加速する大型提携",
      "source": "IR",
      "amount": "開発費製品毎に20億米ドルまでMerckが75%負担"
    },
    {
      "date": "2023/12",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "エンハーツ等が牽引しコア営業利益1953億円に急拡大",
      "detail": "FY2023決算でコア営業利益+59.3%、当期利益+83.8%",
      "significance": "ADCプラットフォーム企業としての収益力が顕在化",
      "source": "IR",
      "amount": "売上16017億円/コア営業利益1953億円"
    },
    {
      "date": "2024/4",
      "category": "組織再編",
      "region": "",
      "importance": 2,
      "event": "第一三共エスファを持分法適用関連会社化",
      "detail": "クオールホールディングスに株式を一部譲渡",
      "significance": "国内ジェネリック事業を持分法化し経営資源をDXd ADCへ集中",
      "source": "有価証券報告書",
      "amount": "株式譲渡益163億円"
    },
    {
      "date": "2024/12",
      "category": "",
      "region": "",
      "importance": 3,
      "event": "ダトロウェイ（Dato-DXd）日本承認取得",
      "detail": "エンハーツに次ぐ2番目のDXd ADC製品",
      "significance": "DXd ADCプラットフォームが単一製品依存から脱却する転換点",
      "source": "IR"
    },
    {
      "date": "2024/12",
      "category": "企業買収",
      "region": "",
      "importance": 2,
      "event": "Glycotopeからgatipotuzumab知的財産権を買取",
      "detail": "6番目のDXd ADC DS-3939の抗体権利を確保",
      "significance": "自社創薬ADCパイプラインの拡充",
      "source": "IR",
      "amount": "対価132.5Mn USD（220億円）"
    },
    {
      "date": "2025/1",
      "category": "",
      "region": "米州",
      "importance": 2,
      "event": "ダトロウェイ米国承認取得",
      "detail": "",
      "significance": "日米欧3極での2製品体制確立に向けた重要ステップ",
      "source": "IR"
    },
    {
      "date": "2025/4",
      "category": "組織再編",
      "region": "",
      "importance": 1,
      "event": "第一三共プロファーマ・第一三共ケミカルファーマを吸収合併",
      "detail": "製造・原薬子会社の本体統合",
      "significance": "",
      "source": "有価証券報告書"
    },
    {
      "date": "2025/4",
      "category": "",
      "region": "欧州",
      "importance": 2,
      "event": "ダトロウェイ欧州承認取得",
      "detail": "",
      "significance": "日米欧3極でのダトロウェイ本格展開開始",
      "source": "IR"
    }
  ]
}